

Substitute for form 1449A&B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet **1**

of

1**Complete if Known**

| | |
|------------------------|--------------------|
| Application Number | 10/551,405 |
| Filing Date | September 29, 2005 |
| First Named Inventor | Berzofsky, Jay A. |
| Art Unit | 1648 |
| Examiner Name | Parkin, Jeffrey S. |
| Attorney Docket Number | 015280-481100US |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ² |
|--------------------|-----------------------|---------------------------|---------------------|-----------------------------------|-----------------------------|---|---|--------------------------|
| | | Country Code ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | AA | WO | 99/51750 | A1 | 04-01-1999 | Harrer | | <input type="checkbox"/> |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|---|--------------------------|
| | AB | BERZOFSKY, Jay A. et al.; "Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections"; 1999, <u>Immunological Reviews</u> , Vol. 170, pp. 151-172. | <input type="checkbox"/> |
| | AC | FIRAT, Huseyin et al.; "Design of a polypeptide construct for the induction of HLA-A*0201-restricted HIV 1-specific CTL responses using <i>HLA-A*0201</i> transgenic, <i>H-2</i> class 1 KO mice"; 2001, <u>Eur. J. Immunol.</u> , Vol. 31, pp. 3064-3074. | <input type="checkbox"/> |
| | AD | HARRER, Ellen et al.; "Recognition of the Highly Conserved YMDD Region in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase by HLA-A2-Restricted Cytotoxic T Lymphocytes from an Asymptomatic Long-Term Nonprogressor Cytotoxic T Lymphocytes from an Asymptomatic Long-Term Nonprogressor"; 1996, <u>The Journal of Infectious Diseases</u> , Vol. 173, pp. 476-479. | <input type="checkbox"/> |
| | AE | OKAZAKI, Takahiro et al.; "Epitope-Enhanced Conserved HIV-1 Peptide Protects HLA-A2-Transgenic Mice Against Virus Expressing HIV-1 Antigen"; 2003, <u>The Journal of Immunologists</u> , pp. 2548-2555. | <input type="checkbox"/> |
| | AF | PASCOLO, Steve et al.; "HLA-A2.1-restricted Education and Cytolytic Activity of CD8 ⁺ T Lymphocytes from β 2 Microglobulin (β 2m) HLA-A2.1 Monochain Transgenic H-2D ^b β 2m Double Knockout Mice"; 1997, <u>J. Exp. Med.</u> , Vol. 185, No. 12, pp. 2043-2051. | <input type="checkbox"/> |
| | AG | RAMMENSEE, Hans Georg; "MHC ligands and peptide motifs: first listing"; 1995, <u>Immunogenetics</u> , Vol. 41, pp. 178-228. | <input type="checkbox"/> |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.